Yun Hak Kim

Mar 15, 2023 | biorxiv.org | Yuna Kim |Yun Hak Kim |Pan Xu |Kwan-Young Jung

New Results doi: https://doi.org/10.1101/2023.03.13.531998 AbstractThe FDA-approved oral multi-kinase inhibitor, sorafenib (BAY 43-9006, Nexavar), is the first approved systemic therapy for patients with unresectable hepatocellular carcinoma (HCC). Although it has been shown to significantly improve the overall survival of patients with HCC, drug resistance limits the response rate to this therapeutic.